RecruitingNCT05570110
Enoxolone or placebo for depression and treatment-response biomarkers
About this title
Read the official source — NCT05570110Medication studyAges 18+Germany
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- MarburgSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 23, 2022
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 80
- Sponsor
- Philipps University Marburg
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Germany
- Age range
- Over 18 Years
- Official registry ID
- NCT05570110
- Official title
Show the full official title
Double-blind Randomized Placebo Controlled Study on the Effect of Enoxolone ( 11-beta Hydroxysteroid-dehydrogenase Type 2 Inhibitor) on the RAAS, Autonomic and Imaging Biomarkers and the Outcome of Depression
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Marburg
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Philipps University Marburg, a university.
Does this study involve medication?
Yes. The study involves medication, including Enoxolone.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as recruiting.
